Literature DB >> 3355273

Clinical stage I melanoma among patients who presented with lesions of Clark levels deep III through V.

R A Evans.   

Abstract

Entities:  

Mesh：

Year:  1988        PMID： 3355273      PMCID： PMC1493429     

Source DB:  PubMed          Journal:  Ann Surg        ISSN： 0003-4932            Impact factor:   12.969


× No keyword cloud information.
  5 in total

1.  Regional lymph node dissection for malignant melanoma of the extremities.

Authors:  D F Roses; M N Harris; S L Gumport; F Michelassi; J A Coffey; N Dubin
Journal:  Surgery       Date:  1981-06       Impact factor: 3.982

2.  Malignant melanoma. Practical considerations concerning prophylactic regional lymph node dissection.

Authors:  A W Silberman
Journal:  Ann Surg       Date:  1987-08       Impact factor: 12.969

3.  Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities.

Authors:  U Veronesi; J Adamus; D C Bandiera; O Brennhovd; E Caceres; N Cascinelli; F Claudio; R L Ikonopisov; V V Javorski; S Kirov; A Kulakowski; J Lacour; F Lejeune; Z Mechl; A Morabito; I Rodé; S Sergeev; E van Slooten; K Szczygiel; N N Trapeznikov; R I Wagner
Journal:  Cancer       Date:  1982-06-01       Impact factor: 6.860

4.  Host resistance to carcinoma of the breast.

Authors:  R A Evans
Journal:  South Med J       Date:  1980-09       Impact factor: 0.954

5.  A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results.

Authors:  F H Sim; W F Taylor; J C Ivins; D J Pritchard; E H Soule
Journal:  Cancer       Date:  1978-03       Impact factor: 6.860
  5 in total
  2 in total

1.  The experience of the University of Alabama with recurrent melanoma.

Authors:  R A Evans
Journal:  Ann Surg       Date:  1996-04       Impact factor: 12.969

Review 2.  Elective lymph node dissection (ELND) for malignant melanoma.

Authors:  R A Evans
Journal:  Ann Surg       Date:  1995-04       Impact factor: 12.969
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.